Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [212]
News [361]
Articles [23]
Editorials [3]
Conferences [65]
elearning [25]
Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory...
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
Treatment options for high risk relapsed/refractory multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
Treatment options for high risk relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
BCMA: A new biomarker for multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019
Transitioning from bortezomib to ixazomib in patients with multiple myeloma
Dr Habte Yimer - Texas Oncology, Tyler, USA
Transitioning from bortezomib to ixazomib in patients with multiple myeloma ( Dr Habte Yimer - Texas Oncology, Tyler, USA )
23 Sep 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )
24 Jun 2019
Chemoimmunotherapy or BTK inhibition for patients with CLL
Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany
Chemoimmunotherapy or BTK inhibition for patients with CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )
20 Jun 2019
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma
Dr Johannes Düll - University of Würzburg, Würzburg, Germany
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )
20 Jun 2019
Blinatumomab for relapsed/refractory Burkitt's lymphoma
Dr Johannes Düll - University of Würzburg, Würzburg, Germany
Blinatumomab for relapsed/refractory Burkitt's lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )
20 Jun 2019
Using bioinformatics and genomics to treat AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
Using bioinformatics and genomics to treat AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )
20 Jun 2019
The changing landscape of AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
The changing landscape of AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )
20 Jun 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation